New Stock News | Sunsun Cold Chain Submits Listing Application to HKEX Again

According to the China Fortune Finance and Economics APP, it was revealed by the Hong Kong Stock Exchange on July 22 that Shanghai ShengSheng Pharmaceutical Cold Chain Technology Co., Ltd. (referred to as ShengSheng Cold Chain) has submitted an application for listing on the Hong Kong Stock Exchange Main Board, with China Jin and Guojin Securities (Hong Kong) as its joint sponsors. The company had previously submitted an application to the Hong Kong Stock Exchange on January 13, 2026. According to the prospectus, ShengSheng Cold Chain is the leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China, with a core focus on clinical trial temperature-controlled supply chain services, as well as extending to commercial medical product temperature-controlled supply chain services, and the research and manufacturing of temperature-controlled equipment and materials. According to data from Frost & Sullivan, based on revenue in 2025, the company is the largest temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China, and the only Chinese enterprise among the top ten clinical trial temperature-controlled supply chain service providers in the world.